Denali therapeutics inc. (DNLI)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Operating activities
Net loss

-56,763

-54,025

-46,260

-58,337

-38,992

77,533

-35,371

-54,724

-23,678

-22,887

-21,844

-22,134

-21,320

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

2,109

2,064

1,890

1,643

2,403

2,364

2,327

1,855

854

825

778

766

731

Stock–based compensation expense

10,785

8,889

8,901

13,714

6,874

5,646

5,510

4,710

2,925

1,457

1,128

1,059

765

Net amortization of discounts on marketable securities

607

987

1,298

1,417

1,317

841

772

705

387

146

-214

-458

-227

Non-cash operating lease expense

-321

-2,333

593

3,005

-1,265

4,620

157

-1,114

-225

0

0

-78

78

Gain on disposal of property and equipment

-

-

-

-

-

-

0

-8

44

-

-

-

-

Other non-cash items

53

-76

114

313

0

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Prepaid expenses and other assets

2,454

-863

-3,108

145

-2,849

12,911

3,661

105

1,613

-76

1,269

693

-1,959

Accounts payable

-292

567

-837

-662

1,965

-1,761

-5,859

8,045

-951

-111

764

272

-718

Accruals and other current liabilities

-3,827

-1,376

4,763

2,706

-4,593

6,474

4,042

1,854

-3,257

2,694

-1,539

3,366

-943

Contract liabilities

-3,069

-3,489

-1,181

-839

-777

11,667

-1,195

-1,648

59,953

-

-

-

-

Operating lease liability

-642

-

-

-

0

-

-

-

-

-

-

-

-

Other non-current liabilities

-

-

-

-

-

-

-

-

-

-226

-154

-585

412

Net cash used in operating activities

-54,492

-47,643

-30,435

-43,175

-30,323

93,185

-34,822

-41,824

33,577

-18,336

-21,921

-17,569

-18,809

Investing activities
Purchases of marketable securities

153,155

150,557

75,110

34,219

109,810

157,293

38,951

33,650

328,036

133,138

18,495

11,207

16,949

Purchases of property and equipment

879

2,773

2,847

10,271

2,028

1,437

847

572

537

1,071

367

569

868

Maturities and sales of marketable securities

140,701

195,715

127,450

108,371

103,791

97,327

84,525

64,750

27,299

39,060

35,388

33,850

33,200

Net cash used in investing activities

-13,333

42,385

49,493

63,881

-8,047

-61,403

44,727

30,528

-301,274

-95,149

16,526

22,074

15,383

Financing activities
Issuance of common stock in connection with the Takeda Collaboration Agreement

-

-

-

-

-

0

0

0

94,406

-

-

-

-

Proceeds from public offering of common stock, net of issuance costs

193,948

-

-

-

0

-

-

-

-

-

-

-

-

Proceeds from exercise of awards under equity incentive plans

1,965

2,034

679

2,569

908

1,690

658

1,432

219

1

357

51

324

Net cash provided by financing activities

195,913

2,034

679

2,569

908

1,690

658

1,432

93,239

295,591

357

51

324

Net increase (decrease) in cash, cash equivalents and restricted cash

128,088

-3,224

19,737

23,275

-37,462

33,472

10,563

-9,864

-174,458

182,106

-5,038

4,556

-3,102

Supplemental disclosures of cash flow information
Tenant improvements provided by the landlord

0

0

2

0

11,341

10,197

4,364

0

0

-

-

-

-

Property and equipment purchases accrued but not yet paid

0

-1,500

-662

593

1,569

298

37

-246

246

-

-

-

98

Common Stock
Payments of issuance costs related to issuance of stock

-

-

-

-

-

0

0

0

1,342

-

-

-

-

Preferred Stock
Payments of issuance costs related to issuance of stock

-

-

-

-

-

0

0

0

44

-

-

-

-